37 results
8-K
EX-99.1
RVMD
Revolution Medicines Inc
8 May 24
Revolution Medicines Reports First Quarter 2024 Financial Results and Update on Corporate Progress
4:05pm
. The company also intends to evaluate RMC-9805 in combination with SOC in one or more tumor types.
RAS Innovation Engine
Beyond the first wave
8-K
EX-99.1
RVMD
Revolution Medicines Inc
26 Feb 24
Revolution Medicines Reports Fourth Quarter and Full Year 2023 Financial Results and Update on Corporate Progress
4:04pm
been reported.
The company expects to disclose initial clinical PK, safety, tolerability, and activity data in the second half of 2024.
RAS Innovation
8-K
EX-99.1
6oyv8g9
6 Nov 23
Revolution Medicines Reports Third Quarter 2023 Financial Results and Update on Corporate Progress
4:05pm
8-K
EX-99.1
9wp67p 03f5fq
8 Aug 23
Revolution Medicines Reports Second Quarter 2023 Financial Results and Update on Corporate Progress
4:04pm
8-K
EX-99.1
pzn3ddyb
8 May 23
Revolution Medicines Reports First Quarter 2023 Financial Results and Update on Corporate Progress
4:04pm
8-K
EX-99.1
asycb7llc
7 Nov 22
Revolution Medicines Reports Third Quarter 2022 Financial Results and Update on Corporate Progress
4:08pm
8-K
EX-99.1
r0xtflsprav jnt
9 Aug 22
Revolution Medicines Reports Second Quarter 2022 Financial Results and Update on Corporate Progress
12:00am
8-K
EX-99.1
30ndvf33dj3p4nxd1zr5
9 May 22
Revolution Medicines Reports First Quarter 2022 Financial Results and Update on Corporate Progress
4:07pm
8-K
EX-99.1
cyjmgro1wcjwikuaiq36
11 Jan 22
Results of Operations and Financial Condition
2:16pm
DEF 14A
9no51yh 158y3s
28 Apr 21
Definitive proxy
4:33pm
424B4
79x0u2vedz61k
5 Feb 21
Prospectus supplement with pricing info
12:00am